Fundamental index

603456.SS Zhejiang Jiuzhou Pharmaceutical Co., Ltd

Healthcare · Drug Manufacturers - Specialty & Generic · CN · as of 2026-08-14

C
Fundamental score
67.6

Reasons

  • Balance 100: debt/equity n/a, current ratio 3.83, Altman Z 6.80
  • Valuation 94: PE n/a, EV/EBITDA n/a, FCF yield 8.2%
  • Quality 48: ROE 7.4%, ROIC n/a, net margin 12.5%

Risk flags

No major cached red flags

Component scores

Quality48
Growth50
Balance100
Valuation94
Cash flow44

Key metrics

ROE
7.4% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
ROICn/a
Net margin
12.5% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
Revenue growthn/a
Debt / equityn/a
Current ratio
3.83 above 1 is generally healthier
03+
risk < 1.0ok >= 1.0strong >= 2.0
Altman Z-score
6.80 higher usually means lower distress risk
04+
distress < 1.8grey 1.8-3.0safer > 3.0
PE ration/a
EV / EBITDAn/a
FCF yield
8.2% higher cash-flow yield is usually better
-5%15%+
weak < 0%ok >= 3%strong >= 8%

Revenue

5.52B 1.86B 1.86B 2.02B 2.65B 4.06B 5.45B 5.52B 5.16B 5.51B 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: revenue values.

Net income

1.03B 157.15M 157.15M 237.79M 380.58M 633.90M 921.17M 1.03B 606.10M 730.07M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: net income values.

Free cash flow

1.16B 34.12M 34.12M 233.71M 84.67M 97.64M 511.99M 430.88M 102.69M 1.16B 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: free cash flow values.

Growth metrics

53.5% -6.6% 8.4% 8.3% 31.3% 53.5% 34.0% 1.4% -6.6% 6.7% 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: growth metrics values.

Abbreviations and definitions

ROE
ROE measures how much net profit a company generates from shareholders' equity.
ROIC
ROIC compares operating profit after tax with the capital invested in the business.
Net margin
Net margin shows how much net profit remains from revenue.
Revenue growth
Revenue growth measures how sales changed versus the comparable prior period.
Debt / equity
Debt to equity compares company debt with shareholders' equity.
Current ratio
Current ratio compares short-term assets with short-term liabilities.
Altman Z-score
Altman Z-score is a model estimating bankruptcy risk from financial ratios.
PE ratio
PE compares market price with earnings per share.
EV / EBITDA
EV/EBITDA compares total company value with operating earnings before depreciation and amortization.
FCF yield
FCF yield compares free cash flow with market value.
Revenue
Revenue is the total amount generated from selling goods or services before expenses.
Net income
Net income is profit after operating costs, interest, taxes and other expenses.
Free cash flow
Free cash flow is cash left after operating cash flow covers capital expenditures.
Growth metrics
Growth metrics summarize changes in revenue, profit or EPS versus a prior period.
EPS
EPS is net income allocated to each share.
EBITDA
EBITDA is earnings before interest, taxes, depreciation and amortization.
TTM
TTM is a rolling last-12-month view instead of one fiscal year.

This page is an automated factual summary of cached FMP data, not investment advice. Always verify source filings and liquidity before making decisions.